{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:09:14Z","timestamp":1762880954435,"version":"3.45.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s10384-025-01225-z","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T23:12:44Z","timestamp":1749683564000},"page":"876-885","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors determining timing of first recurrence after three loading aflibercept injections in newly diagnosed neovascular age-related macular degeneration"],"prefix":"10.1007","volume":"69","author":[{"given":"Sang Hyeok","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4658-7497","authenticated-orcid":false,"given":"Mee Yon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"1225_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1001\/archopht.122.4.477","volume":"122","author":"N Congdon","year":"2004","unstructured":"Congdon N, O\u2019Colmain B, Klaver C, Klein R, Munoz B, Friedman DS, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477\u201385.","journal-title":"Arch Ophthalmol"},{"key":"1225_CR2","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.oret.2019.01.018","volume":"3","author":"PG Traine","year":"2019","unstructured":"Traine PG, Pfister IB, Zandi S, Spindler J, Garweg JG. Long-term outcome of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a \u201ctreat-and-extend\u201d regimen. Ophthalmol Retina. 2019;3:393\u20139.","journal-title":"Ophthalmol Retina."},{"key":"1225_CR3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","volume":"121","author":"JE Grunwald","year":"2014","unstructured":"Grunwald JE, Daniel E, Huang J, Ying G, Maguire MG, Toth CA, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121:150\u201361.","journal-title":"Ophthalmology"},{"key":"1225_CR4","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1097\/IAE.0000000000000627","volume":"35","author":"KB Freund","year":"2015","unstructured":"Freund KB, Korobelnik J-F, Devenyi R, Framme C, Galic J, Herbert E, et al. Treat-and-extend regimens with anti-VEGF agents in retinal diseases: a literature review and consensus recommendations. Retina. 2015;35:1489\u2013506.","journal-title":"Retina"},{"key":"1225_CR5","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1136\/bjophthalmol-2015-308166","volume":"100","author":"FG Holz","year":"2016","unstructured":"Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Hykin P, et al. Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. Br J Ophthalmol. 2016;100:1623\u20138.","journal-title":"Br J Ophthalmol"},{"key":"1225_CR6","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik J-F, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537\u201348.","journal-title":"Ophthalmology"},{"key":"1225_CR7","doi-asserted-by":"publisher","first-page":"7754","DOI":"10.1167\/iovs.12-10895","volume":"53","author":"O Comyn","year":"2012","unstructured":"Comyn O, Heng LZ, Ikeji F, Bibi K, Hykin PG, Bainbridge JW, et al. Repeatability of spectralis OCT measurements of macular thickness and volume in diabetic macular edema. Invest Ophthalmol Vis Sci. 2012;53:7754\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1225_CR8","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1097\/IAE.0000000000003194","volume":"41","author":"PK Kaiser","year":"2021","unstructured":"Kaiser PK, Wykoff CC, Singh RP, Khanani AM, Do DV, Patel H, et al. Retinal fluid and thickness as measures of disease activity in neovascular age-related macular degeneration. Retina. 2021;41:1579\u201386.","journal-title":"Retina"},{"key":"1225_CR9","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/j.ophtha.2006.10.055","volume":"114","author":"DRCR Network","year":"2007","unstructured":"Network DRCR. Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. Ophthalmology. 2007;114:1520\u20135.","journal-title":"Ophthalmology"},{"key":"1225_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12886-019-1089-y","volume":"19","author":"J Yu","year":"2019","unstructured":"Yu J, Lei Y, Chang Q, Xu G, Ye X, Li L, et al. The relationship between foveal outer nuclear layer thickness in the active and resolved phases of central serous chorioretinopathy treated with half-dose photodynamic therapy. BMC Ophthalmol. 2019;19:1\u20136.","journal-title":"BMC Ophthalmol"},{"key":"1225_CR11","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1136\/bjophthalmol-2012-301857","volume":"96","author":"H Nazari","year":"2012","unstructured":"Nazari H, Rao NA. Resolution of subretinal fluid with systemic corticosteroid treatment in acute Vogt\u2013Koyanagi\u2013Harada disease. Br J Ophthalmol. 2012;96:1410\u20134.","journal-title":"Br J Ophthalmol"},{"key":"1225_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10792-010-9412-x","volume":"31","author":"J Ikewaki","year":"2011","unstructured":"Ikewaki J, Kimoto K, Choshi T, Nagata M, Motomura Y, Tamura K, et al. Optical coherence tomographic assessment of dynamic macular changes in patients with Vogt\u2013Koyanagi\u2013Harada disease. Int Ophthalmol. 2011;31:9\u201313.","journal-title":"Int Ophthalmol"},{"key":"1225_CR13","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1097\/IAE.0b013e3182953df4","volume":"33","author":"DJ Warrow","year":"2013","unstructured":"Warrow DJ, Hoang QV, Freund KB. Pachychoroid pigment epitheliopathy. Retina. 2013;33:1659\u201372.","journal-title":"Retina"},{"key":"1225_CR14","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1097\/IAE.0000000000000409","volume":"35","author":"GK Broadhead","year":"2015","unstructured":"Broadhead GK, Hong T, Zhu M, Li H, Schlub TE, Wijeyakumar W, et al. Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degeneration. Retina. 2015;35:975\u201381.","journal-title":"Retina"},{"key":"1225_CR15","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.ajo.2007.02.024","volume":"143","author":"R Spaide","year":"2007","unstructured":"Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol. 2007;143:679\u201380.","journal-title":"Am J Ophthalmol"},{"issue":"309\u201318","key":"1225_CR16","volume":"158","author":"G Coscas","year":"2014","unstructured":"Coscas G, Yamashiro K, Coscas F, De Benedetto U, Tsujikawa A, Miyake M, et al. Comparison of exudative age-related macular degeneration subtypes in Japanese and French Patients: multicenter diagnosis with multimodal imaging. Am J Ophthalmol. 2014;158(309\u201318): e2.","journal-title":"Am J Ophthalmol"},{"key":"1225_CR17","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3341\/jkos.2010.51.4.516","volume":"51","author":"KH Park","year":"2010","unstructured":"Park KH, Song SJ, Lee WK, Yoon HS, Koh HJ, Kim CG, et al. The results of nation-wide registry of age-related macular degeneration in Korea. J Korean Ophthalmol Soc. 2010;51:516\u201323.","journal-title":"J Korean Ophthalmol Soc"},{"key":"1225_CR18","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.ophtha.2010.09.012","volume":"118","author":"SE Chung","year":"2011","unstructured":"Chung SE, Kang SW, Lee JH, Kim YT. Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Ophthalmology. 2011;118:840\u20135.","journal-title":"Ophthalmology"},{"key":"1225_CR19","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1016\/j.ophtha.2015.05.012","volume":"122","author":"L Ma","year":"2015","unstructured":"Ma L, Li Z, Liu K, Rong SS, Brelen ME, Young AL, et al. Association of genetic variants with polypoidal choroidal vasculopathy: a systematic review and updated meta-analysis. Ophthalmology. 2015;122:1854\u201365.","journal-title":"Ophthalmology"},{"key":"1225_CR20","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1136\/bjo.2004.049296","volume":"89","author":"M Yuzawa","year":"2005","unstructured":"Yuzawa M, Mori R, Kawamura A. The origins of polypoidal choroidal vasculopathy. Br J Ophthalmol. 2005;89:602\u20137.","journal-title":"Br J Ophthalmol"},{"key":"1225_CR21","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","volume":"136","author":"WK Lee","year":"2018","unstructured":"Lee WK, Iida T, Ogura Y, Chen S-J, Wong TY, Mitchell P, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial. JAMA Ophthalmol. 2018;136:786\u201393.","journal-title":"JAMA Ophthalmol."},{"key":"1225_CR22","first-page":"485","volume":"8","author":"P Tranos","year":"2013","unstructured":"Tranos P, Vacalis A, Asteriadis S, Koukoula S, Vachtsevanos A, Perganta G, et al. Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration. Drug Des Devel Ther. 2013;8:485\u201390.","journal-title":"Drug Des Devel Ther."},{"key":"1225_CR23","doi-asserted-by":"publisher","first-page":"21572","DOI":"10.1038\/s41598-021-00904-4","volume":"11","author":"JY Kim","year":"2021","unstructured":"Kim JY, Son WY, Kim RY, Kim M, Park YG, Park Y-H. Recurrence and visual prognostic factors of polypoidal choroidal vasculopathy: 5-year results. Sci Rep. 2021;11:21572.","journal-title":"Sci Rep"},{"key":"1225_CR24","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1089\/jop.2016.0098","volume":"33","author":"JH Kim","year":"2017","unstructured":"Kim JH, Chang YS, Lee DW, Kim CG, Kim JW. Incidence and timing of the first recurrence in neovascular age-related macular degeneration: comparison between ranibizumab and aflibercept. J Ocul Pharmacol Ther. 2017;33:445\u201351.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1225_CR25","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/j.ophtha.2015.06.053","volume":"122","author":"Y Kuroda","year":"2015","unstructured":"Kuroda Y, Yamashiro K, Miyake M, Yoshikawa M, Nakanishi H, Oishi A, et al. Factors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth factor treatment: a retrospective cohort study. Ophthalmology. 2015;122:2303\u201310.","journal-title":"Ophthalmology"},{"key":"1225_CR26","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1089\/jop.2021.0051","volume":"37","author":"JH Kim","year":"2021","unstructured":"Kim JH, Kim JW, Kim CG. Five-year reactivation after ranibizumab or aflibercept treatment for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. J Ocul Pharmacol Ther. 2021;37:525\u201333.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1225_CR27","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1097\/IAE.0000000000002195","volume":"38","author":"AM Khanani","year":"2018","unstructured":"Khanani AM, Eichenbaum D, Schlottmann PG, Tuomi L, Sarraf D. Optimal management of pigment epithelial detachments in eyes with neovascular age-related macular degeneration. Retina. 2018;38:2103.","journal-title":"Retina"},{"key":"1225_CR28","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1097\/IAE.0b013e3182993f66","volume":"33","author":"S Mrejen","year":"2013","unstructured":"Mrejen S. Multimodal imaging of pigment epithelial detachment: a guide to evaluation. Retina. 2013;33:1735\u201362.","journal-title":"Retina"},{"key":"1225_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2021.101216","volume":"24","author":"S Davoudi","year":"2021","unstructured":"Davoudi S, Roohipourmoallai R, Guerin CM, Iyer SS. Exacerbation of pigment epithelial detachment following aflibercept: a case of bevacizumab rescue. Am J Ophthalmol Case Rep. 2021;24: 101216.","journal-title":"Am J Ophthalmol Case Rep."},{"key":"1225_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12886-018-0824-0","volume":"18","author":"P Tyagi","year":"2018","unstructured":"Tyagi P, Juma Z, Hor YK, Scott NW, Ionean A, Santiago C. Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from ranibizumab to aflibercept. BMC Ophthalmol. 2018;18:1\u20138.","journal-title":"BMC Ophthalmol"},{"key":"1225_CR31","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1089\/jop.2019.0158","volume":"36","author":"JH Kim","year":"2020","unstructured":"Kim JH, Kim JW, Kim CG, Lee DW. Decreased periodicity of reactivation interval in neovascular age-related macular degeneration in patients with a late first reactivation after initial treatment. J Ocul Pharmacol Ther. 2020;36:703\u201310.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1225_CR32","doi-asserted-by":"publisher","first-page":"5045","DOI":"10.1038\/s41598-023-32184-5","volume":"13","author":"S Lee","year":"2023","unstructured":"Lee S, Kim KT, Kim DY, Chae JB, Seo EJ. Outer nuclear layer recovery as a predictor of visual prognosis in type 1 choroidal neovascularization of neovascular age-related macular degeneration. Sci Rep. 2023;13:5045.","journal-title":"Sci Rep"},{"key":"1225_CR33","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00417-010-1588-2","volume":"249","author":"R H\u00f6rster","year":"2011","unstructured":"H\u00f6rster R, Ristau T, Sadda SR, Liakopoulos S. Individual recurrence intervals after anti-VEGF therapy for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2011;249:645\u201352.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1225_CR34","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00417-012-2090-9","volume":"251","author":"I Mantel","year":"2013","unstructured":"Mantel I, Deli A, Iglesias K, Ambresin A. Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2013;251:697\u2013704.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1225_CR35","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41433-021-01879-2","volume":"37","author":"M Choi","year":"2023","unstructured":"Choi M, Kim S-W, Yun C, Oh J-H, Oh J. Predictive role of optical coherence tomography angiography for exudation recurrence in patients with type 1 neovascular age-related macular degeneration treated with pro-re-nata protocol. Eye (Lond). 2023;37:34\u201341.","journal-title":"Eye (Lond)"},{"key":"1225_CR36","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/IAE.0000000000000287","volume":"35","author":"M Lehmann","year":"2015","unstructured":"Lehmann M, Bousquet E, Beydoun T, Behar-Cohen F. PACHYCHOROID: an inherited condition? Retina. 2015;35:10\u20136.","journal-title":"Retina"},{"key":"1225_CR37","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/j.ophtha.2015.05.042","volume":"122","author":"AS Willoughby","year":"2015","unstructured":"Willoughby AS, Ying G, Toth CA, Maguire MG, Burns RE, Grunwald JE, et al. Subretinal hyperreflective material in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2015;122:1846\u201353.","journal-title":"Ophthalmology"},{"key":"1225_CR38","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1097\/IAE.0000000000000166","volume":"34","author":"VP Shah","year":"2014","unstructured":"Shah VP, Shah SA, Mrejen S, Freund KBJR. Subretinal hyperreflective exudation associated with neovascular age-related macular degeneration. Retina. 2014;34:1281\u20138.","journal-title":"Retina"},{"key":"1225_CR39","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.4103\/ijo.IJO_3156_20","volume":"69","author":"D Alex","year":"2021","unstructured":"Alex D, Giridhar A, Gopalakrishnan M, Indurkhya S, Madan S. Subretinal hyperreflective material morphology in neovascular age-related macular degeneration: a case control study. Indian J Ophthalmol. 2021;69:1862.","journal-title":"Indian J Ophthalmol"},{"key":"1225_CR40","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1080\/09273948.2021.1980813","volume":"31","author":"A Arora","year":"2023","unstructured":"Arora A, Agarwal A, Bansal R, Katoch D, Marchese A, Aggarwal K, et al. Subretinal hyperreflective material (SHRM) as biomarker of activity in exudative and non-exudative inflammatory choroidal neovascularization. Ocul Immunol Inflamm. 2023;31:48\u201355.","journal-title":"Ocul Immunol Inflamm"},{"key":"1225_CR41","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/IAE.0000000000000742","volume":"36","author":"KK Dansingani","year":"2016","unstructured":"Dansingani KK, Balaratnasingam C, Naysan J, Freund KB. En face imaging of pachychoroid spectrum disorders with swept-source optical coherence tomography. Retina. 2016;36:499\u2013516.","journal-title":"Retina"},{"key":"1225_CR42","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1136\/bjophthalmol-2016-309818","volume":"101","author":"AY Lee","year":"2017","unstructured":"Lee AY, Lee CS, Egan CA, Bailey C, Johnston RL, Natha S, et al. UK AMD\/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice. Br J Ophthalmol. 2017;101:1683\u20138.","journal-title":"Br J Ophthalmol"},{"key":"1225_CR43","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/eye.2017.81","volume":"31","author":"M Ashraf","year":"2017","unstructured":"Ashraf M, Souka A. Aflibercept in age-related macular degeneration: evaluating its role as a primary therapeutic option. Eye (Lond). 2017;31:1523\u201336.","journal-title":"Eye (Lond)"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01225-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-025-01225-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01225-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:04:43Z","timestamp":1762880683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-025-01225-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1225"],"URL":"https:\/\/doi.org\/10.1007\/s10384-025-01225-z","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"type":"print","value":"0021-5155"},{"type":"electronic","value":"1613-2246"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S. H. Lee, None; M. Y. Lee, None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}